Our resource hub to discover reports, policy papers and other forms of informative content
The private drug insurance market in Canada saw a 7.3% total cost growth in 2023-2024, primarily driven by increased utilization which accounted for 60% of total cost growth. The number of claimants rose by 3.5%, with claimants making
0.9% more claims.
Annual cost growth in Canada’s private drug benefit market is driven by increased utilization and chronic disease drugs, with an increase in claimants post‑pandemic.
Read the full report.
IMC contracted Reformulary Group to analyze the cost of a private plan prescription drug claim in Canada, and separately in Quebec. This report summarizes that analysis.
Reimagining Canada’s Approval and Reimbursement System for Innovative Medicines February 2022
The 2021 Cost Drivers report highlights the consistent annual cost growth in the Canadian private drug benefits market and outlines factors that contribute to price increases.
The 2016–2019 Cost Drivers report highlights annual cost growth in the Canadian private drug benefits market and outlines factors that contribute to price increases.
Informative content to keep you up to date on the most pressing issues facing our industry.
